Alkermes Gets FDA Approval for Schizophrenia Treatment Aristada

Alkermes (ALKS), a biopharmaceutical company, said Tuesday the U.S. Food and Drug Administration has approved ARISTADA extended-release injectable suspension to treat schizophrenia.

The company is preparing to launch the drug immediately.

Shares were 7.9% lower in midday trade, below the midpoint of the 52-week range of $38.49 – $75.17.

Companies: Alkermes plc
Price: 54.91 Price Change: -4.86 Percent Change: -8.13